Page last updated: 2024-12-08

4-n-butylresorcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-n-butylresorcinol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID205912
CHEMBL ID450195
CHEBI ID81689
SCHEMBL ID68792
MeSH IDM0495396

Synonyms (47)

Synonym
AC-349
18979-61-8
4-butylresorcinol
4-butylresorcin
brn 1942645
resorcinol, 4-butyl-
butylresorcinol
bdbm50248158
4-butylbenzene-1,3-diol ,
chebi:81689 ,
n-butylresorcinol
rucinol
CHEMBL450195 ,
AKOS006277916
2ik4uq3zga ,
4-06-00-06003 (beilstein handbook reference)
unii-2ik4uq3zga
1,3-dihydroxy-4-n butyl benzene
ec 606-191-2
4-n-butylresorcinol
rucinol (tn)
C18343
A813362
B3773
4-n-butylresorcinol [who-dd]
vivinol
1,3-benzenediol, 4-butyl-
4-butylresorcinol [inci]
S4997
SCHEMBL68792
CSHZYWUPJWVTMQ-UHFFFAOYSA-N
Q-200189
CS-7786
DTXSID50172403
mfcd01684800
4-butylresorcinol, analytical standard
HY-107369
BCP08128
1,3-benzenediol, 4-butyl-;butylresorcinol;4-n-butylresorcinol;4-butylbenzene-1,3-diol;2,4-dihydroxy-n-butyl benzen
Q2171802
AS-10742
AMY472
HMS3749K09
CCG-266331
4-butylresorcinol;4-n-butylresorcinol, rucinol
NCGC00599698-01
SY054111

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No adverse reactions were observed throughout the study."( Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial.
Huh, CH; Huh, SY; Na, JI; Park, KC; Shin, JW; Youn, SW, 2010
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The preliminary evaluation results of acute toxicity showed the representative 3d and 3j were non-toxic in mice dosed at 1,200 mg/kg."( Synthesis and biological evaluation of unsymmetrical curcumin analogues as tyrosinase inhibitors.
Chen, Q; Conney, AH; Du, Z; Jiang, Y; Lu, Y; Xue, G; Zhang, K; Zheng, X, 2013
)
0.39
" However, because of limited loading capacity of drugs within microsized structures, only a small dosage can be delivered, which is often insufficient for patients."( Enhanced Transdermal Delivery by Combined Application of Dissolving Microneedle Patch on Serum-Treated Skin.
Baek, JH; Choi, YW; Dangol, M; Jang, M; Jung, H; Kang, G; Kim, CH; Kim, S; Kim, SJ; Koh, J; Lahiji, SF; Lee, SG; Li, C; Ma, Y; Ryu, JH; Yang, H, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)0.15000.03403.987110.0000AID395015
TyrosinaseHomo sapiens (human)IC50 (µMol)21.00000.02304.459310.0000AID1611943; AID1717717
TyrosinaseHomo sapiens (human)Ki9.10001.70004.73339.1000AID1717709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1717709Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID654752Antimelanogenic activity in mouse B16 cells assessed as inhibition of melanogenesis2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Adamantyl N-benzylbenzamide: new series of depigmentation agents with tyrosinase inhibitory activity.
AID1611949Potency index, ratio of kojic acid IC50 to compound IC50 for human tyrosinase2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID1717717Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by MBTH based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID395015Inhibition of mushroom tyrosinase activity after 20 mins2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID1611943Inhibition of human tyrosinase2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID395017Cytotoxicity against C57BL/6J mouse Melan-a cells assessed as cell survival at 80 uM by modified crystal violet assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID1717719Inhibition of mushroom tyrosinase2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID395016Inhibition of melanin formation in C57BL/6J mouse Melan-a cells2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (13.04)29.6817
2010's15 (65.22)24.3611
2020's5 (21.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.58 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index77.85 (26.88)
Search Engine Supply Index3.27 (0.95)

This Compound (36.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (30.43%)5.53%
Reviews2 (8.70%)6.00%
Case Studies1 (4.35%)4.05%
Observational0 (0.00%)0.25%
Other13 (56.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]